Osteal raises $50m to bring joint infection drug/device combo to market

06 Jun 2024
www.pharmaceutical-technology.com
Clinical ResultPhase 3Fast TrackOrphan DrugVaccine
Osteal raises $50m to bring joint infection drug/device combo to market
Preview
Source: Pharmaceutical Technology
Osteal antibiotic joint spacer aims to treat periprosthetic joint infection. Image credit: Shutterstock / Kateryna Kon.
Osteal Therapeutics has raised $50m in Series D financing, as the orthopaedic infection treatment specialist turns its eyes to a regulatory submission for its lead candidate VT-X7.
Recommended Buyer's Guides
Osteal raises $50m to bring joint infection drug/device combo to market
Preview
Source: Pharmaceutical Technology
Buyer's Guide
Leading Guide to Packaging Materials, Containers and Containment Services for the Pharmaceutical Industry
Osteal raises $50m to bring joint infection drug/device combo to market
Preview
Source: Pharmaceutical Technology
Buyer's Guide
Leading Guide to Clinical Packaging Companies in contract Manufacturing for the Pharmaceutical Industry
Medtech giant Zimmer Biomet led the round with participation from existing investors, including Johnson & Johnson Innovation, among others.
The funds, which follow $23m raised in Series C financing in late 2023, will be used for a new drug application (NDA) to the US Food and Drug Administration (FDA) for VT-X7. Proceeds will also go towards advancing the US-based company’s musculoskeletal portfolio, according to a 5 June press release.
Osteal has designed VT-X7 for the treatment of periprosthetic joint infection. The condition is a complication of joint replacement surgery in which bacteria infiltrate the joint implant. This causes biofilms, a layer of microorganisms that are hard to treat.
VT-X7 is a drug/device combination product, consisting of antibiotic drugs vancomycin hydrochloride and tobramycin sulfate for irrigation and the VT-X7 irrigation system. The therapy works by placing a spacer connected to an irrigation pump. Antibiotics are then administered into the joint space through the spacer for seven days of treatment.
See Also:FDA recommends updated Covid-19 vaccinesCovid-19 vaccines targeting JN.1
Osteal raises $50m to bring joint infection drug/device combo to market
Preview
Source: Pharmaceutical Technology
India’s DCGI approves Orchid Pharma’s API Enmetazobactam
Osteal raises $50m to bring joint infection drug/device combo to market
Preview
Source: Pharmaceutical Technology
Osteal says the product can deliver high antibiotic concentrations at the infection site and is effective against both gram-negative and gram-positive bacteria.
The company’s candidate has breakthrough therapy, orphan drug, fast track, and qualified infectious disease product designations, indicating that the company is eligible for a range of benefits on expedited regulatory pathways.
VT-X7 recently demonstrated positive results in a Phase III trial, named APEX-2 (NCT05607030). The trial, which enrolled 76 patients scheduled for a two-stage exchange arthroplasty due to hip or knee periprosthetic joint infection, met its primary endpoint of treatment success after 180 days. The trial is expected to end in late 2024, at which point Osteal said it will seek FDA approval.
Osteal’s CEO David Thompson said: “This round of financing represents an inflection point in the company’s progress towards introducing VT-X7 to the market.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.